Terbutaline accumulates in blood and urine following daily therapeutic inhalation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Terbutaline accumulates in blood and urine following daily therapeutic inhalation. / Krogh, Nanna; Rzeppa, Sebastian; Dyreborg, Anders; Dehnes, Yvette; Hemmersbach, Peter; Backer, Vibeke; Hostrup, Morten.

I: Medicine and Science in Sports and Exercise, Bind 49, Nr. 6, 2017, s. 1236-1243.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Krogh, N, Rzeppa, S, Dyreborg, A, Dehnes, Y, Hemmersbach, P, Backer, V & Hostrup, M 2017, 'Terbutaline accumulates in blood and urine following daily therapeutic inhalation', Medicine and Science in Sports and Exercise, bind 49, nr. 6, s. 1236-1243. https://doi.org/10.1249/MSS.0000000000001199

APA

Krogh, N., Rzeppa, S., Dyreborg, A., Dehnes, Y., Hemmersbach, P., Backer, V., & Hostrup, M. (2017). Terbutaline accumulates in blood and urine following daily therapeutic inhalation. Medicine and Science in Sports and Exercise, 49(6), 1236-1243. https://doi.org/10.1249/MSS.0000000000001199

Vancouver

Krogh N, Rzeppa S, Dyreborg A, Dehnes Y, Hemmersbach P, Backer V o.a. Terbutaline accumulates in blood and urine following daily therapeutic inhalation. Medicine and Science in Sports and Exercise. 2017;49(6):1236-1243. https://doi.org/10.1249/MSS.0000000000001199

Author

Krogh, Nanna ; Rzeppa, Sebastian ; Dyreborg, Anders ; Dehnes, Yvette ; Hemmersbach, Peter ; Backer, Vibeke ; Hostrup, Morten. / Terbutaline accumulates in blood and urine following daily therapeutic inhalation. I: Medicine and Science in Sports and Exercise. 2017 ; Bind 49, Nr. 6. s. 1236-1243.

Bibtex

@article{100caf5d4d9646d38fad172189be5987,
title = "Terbutaline accumulates in blood and urine following daily therapeutic inhalation",
abstract = "PURPOSE: This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men.METHODS: Twelve healthy young trained men underwent two pharmacokinetic trials comparing single dose (2 mg) and seven consecutive days (2 mg×d) of inhaled terbutaline. After inhalation of terbutaline at each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption after which they stayed inactive. Blood and urine samples were collected before and after inhalation of terbutaline. Samples were analyzed by high performance liquid chromatography-tandem mass spectrometry.RESULTS: Maximum serum concentration of terbutaline (Cmax) (6.4 (±1.2) vs. 4.9 (±1.2) ng×mL, P = 0.01) (mean (±95% confidence interval)) and area under serum concentration-time curve from 0 to 4 hours after inhalation (AUC0-4) (16 (±3) vs. 13 (±2) ng×mL×h, P ≤ 0.005) were higher after seven days of inhalation compared to the first day. Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after seven days of inhalation compared to the first day (274 ± (43) vs. 194 (±33) μg, P ≤ 0.001). These differences were partly attributed to systemic accumulation of terbutaline after consecutive days of inhalation, in that baseline serum and urine samples revealed incomplete elimination of terbutaline.CONCLUSION: Terbutaline accumulates in serum and urine after consecutive days of inhalation. For doping control purposes, these observations are of relevance if a urine threshold and decision limit is to be introduced for terbutaline on the World Anti-Doping Agency's list of prohibited substances, since asthmatic athletes may use their bronchorelievers for consecutive days.",
keywords = "Faculty of Science, Beta2-agonist, Asthma, Sports, WADA, HPLC",
author = "Nanna Krogh and Sebastian Rzeppa and Anders Dyreborg and Yvette Dehnes and Peter Hemmersbach and Vibeke Backer and Morten Hostrup",
note = "CURIS 2017 NEXS 141",
year = "2017",
doi = "10.1249/MSS.0000000000001199",
language = "English",
volume = "49",
pages = "1236--1243",
journal = "Medicine and Science in Sports and Exercise",
issn = "0195-9131",
publisher = "Lippincott Williams & Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Terbutaline accumulates in blood and urine following daily therapeutic inhalation

AU - Krogh, Nanna

AU - Rzeppa, Sebastian

AU - Dyreborg, Anders

AU - Dehnes, Yvette

AU - Hemmersbach, Peter

AU - Backer, Vibeke

AU - Hostrup, Morten

N1 - CURIS 2017 NEXS 141

PY - 2017

Y1 - 2017

N2 - PURPOSE: This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men.METHODS: Twelve healthy young trained men underwent two pharmacokinetic trials comparing single dose (2 mg) and seven consecutive days (2 mg×d) of inhaled terbutaline. After inhalation of terbutaline at each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption after which they stayed inactive. Blood and urine samples were collected before and after inhalation of terbutaline. Samples were analyzed by high performance liquid chromatography-tandem mass spectrometry.RESULTS: Maximum serum concentration of terbutaline (Cmax) (6.4 (±1.2) vs. 4.9 (±1.2) ng×mL, P = 0.01) (mean (±95% confidence interval)) and area under serum concentration-time curve from 0 to 4 hours after inhalation (AUC0-4) (16 (±3) vs. 13 (±2) ng×mL×h, P ≤ 0.005) were higher after seven days of inhalation compared to the first day. Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after seven days of inhalation compared to the first day (274 ± (43) vs. 194 (±33) μg, P ≤ 0.001). These differences were partly attributed to systemic accumulation of terbutaline after consecutive days of inhalation, in that baseline serum and urine samples revealed incomplete elimination of terbutaline.CONCLUSION: Terbutaline accumulates in serum and urine after consecutive days of inhalation. For doping control purposes, these observations are of relevance if a urine threshold and decision limit is to be introduced for terbutaline on the World Anti-Doping Agency's list of prohibited substances, since asthmatic athletes may use their bronchorelievers for consecutive days.

AB - PURPOSE: This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men.METHODS: Twelve healthy young trained men underwent two pharmacokinetic trials comparing single dose (2 mg) and seven consecutive days (2 mg×d) of inhaled terbutaline. After inhalation of terbutaline at each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption after which they stayed inactive. Blood and urine samples were collected before and after inhalation of terbutaline. Samples were analyzed by high performance liquid chromatography-tandem mass spectrometry.RESULTS: Maximum serum concentration of terbutaline (Cmax) (6.4 (±1.2) vs. 4.9 (±1.2) ng×mL, P = 0.01) (mean (±95% confidence interval)) and area under serum concentration-time curve from 0 to 4 hours after inhalation (AUC0-4) (16 (±3) vs. 13 (±2) ng×mL×h, P ≤ 0.005) were higher after seven days of inhalation compared to the first day. Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after seven days of inhalation compared to the first day (274 ± (43) vs. 194 (±33) μg, P ≤ 0.001). These differences were partly attributed to systemic accumulation of terbutaline after consecutive days of inhalation, in that baseline serum and urine samples revealed incomplete elimination of terbutaline.CONCLUSION: Terbutaline accumulates in serum and urine after consecutive days of inhalation. For doping control purposes, these observations are of relevance if a urine threshold and decision limit is to be introduced for terbutaline on the World Anti-Doping Agency's list of prohibited substances, since asthmatic athletes may use their bronchorelievers for consecutive days.

KW - Faculty of Science

KW - Beta2-agonist

KW - Asthma

KW - Sports

KW - WADA

KW - HPLC

U2 - 10.1249/MSS.0000000000001199

DO - 10.1249/MSS.0000000000001199

M3 - Journal article

C2 - 28072631

VL - 49

SP - 1236

EP - 1243

JO - Medicine and Science in Sports and Exercise

JF - Medicine and Science in Sports and Exercise

SN - 0195-9131

IS - 6

ER -

ID: 172402958